Tests radiotherapy added to radioiodine in thyroid cancer
Tests extra radiation after surgery in people with high-risk thyroid cancer.
Plain-language title generated from the registry record
Registry title: Adjuvant Radiotherapy in High Risk Locally Advanced DTC
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 80 years old?
Source: NCT06558981, who can take part
Where in China
- Fudan Univeristy Shanghai Cancer CenterShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fudan University
- Trial code
- NCT06558981
- Record updated
- 27 February 2026
- Original description
This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. Patients who meet the inclusion criteria were randomly assigned 1:1 to either the experimental group (adjuvant radiotherapy+RAI) or the control group (RAI), with LRFS as the primary endpoint of the study.Read full original descriptionShow less
The Role of Adjuvant Radiotherapy in High Risk Locally Advanced Differentiated Thyroid Cancer：a 1:1 Randomized Phase III Clinical Trial
This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer. Patients who meet the inclusion criteria were randomly assigned 1:1 to either the experimental group (adjuvant radiotherapy+RAI) or the control group (RAI), with LRFS as the primary endpoint of the study.
Inclusion: The patient voluntarily joined this study and signed an informed consent form; Age: ≥ 14 years old,<80 years old, male or female not limited; Histopathological diagnosis of differentiated thyroid cancer; Surgical total or near total thyroidectomy; The surgery did not achieve R0 resection, and R1/ R2 resection was performed. The volume of residual tumor in R2 resected patients is less than 2cm3; The main organ functions are normal; Good compliance and cooperation with follow-up.
Exclusion: Previously received radiation therapy for the head and neck area; Previously received 131I treatment; Previously received or currently receiving targeted therapy, immunotherapy, chemotherapy; Individuals with claustrophobia who are unable to undergo radiation therapy; Differentiated thyroid cancer with poorly differentiated, or undifferentiated components; Within 5 years or simultaneously suffering from other active malignant tumors. Cured local tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, can be included in the group; Other physical illnesses that affect patients' ability to receive standard treatment; According to the researchers' assessment, there may be other factors that could force the subjects to terminate the study, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the safety of the subjects or the collection of experimental data; There is distant metastasis; Pregnant or lactating women; Patients deemed unsuitable for inclusion by other attending physicians.